A heart transplant is a life-saving procedure, but it is not a permanent cure.

Health · Published 3 October 2026 Swipe more like this →

In short: Replacing a failing heart with a donor organ is the gold standard for end-stage heart failure. While this major surgery can significantly extend life, it requires a lifelong commitment to immunosuppressant medication and careful monitoring to manage the constant risk of organ rejection and other long-term complications.

Heart transplantation is reserved for patients with advanced heart disease when standard treatments, such as medications or pacemakers, fail to improve their condition. The procedure typically involves replacing a patient's damaged heart with one from a recently deceased donor. While orthotopic transplantation—where the original heart is removed—is the standard, surgeons occasionally perform heterotopic or 'piggyback' procedures, leaving the diseased heart in place to support the new one. Because donor hearts are scarce, patients often face long waiting lists, during which time mechanical pumps like ventricular assist devices (VADs) may be used as a bridge to keep them alive.

The primary challenge following surgery is the body's immune response. The immune system may identify the donor heart as a foreign object, leading to rejection. To combat this, recipients must take immunosuppressants for life. While these drugs are essential, they carry significant side effects, including an increased risk of infections, kidney damage, and certain cancers. Furthermore, recipients face the risk of cardiac allograft vasculopathy, a condition where the arteries in the donor heart thicken and harden, potentially leading to heart attacks or failure. Because rejection often occurs without symptoms, patients require frequent biopsies during the first year to monitor their heart tissue.

The field has evolved significantly since the first human-to-human transplant in 1967. Breakthroughs like the introduction of cyclosporine in 1983 revolutionized outcomes by allowing for lower doses of corticosteroids, reducing rejection rates. Today, approximately 5,000 heart transplants are performed annually worldwide, with more than half occurring in the United States. Emerging research is now exploring the role of the gut microbiome in influencing post-transplant outcomes, suggesting that future care may involve microbiome-targeted interventions to better manage inflammation and optimize long-term health for transplant recipients.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• Transplants save lives—but supply meets only a fraction of need
• A kidney transplant is not a permanent cure but a bridge to better living
• From bridge to destination: the rise of the implantable artificial heart
• Why a genetically modified pig heart might be the future of medicine
• Can portable technology solve the critical race against time in organ transplants?
• Hospice care is not just for the final days of an incurable illness
• Why your blood sugar levels are the ultimate indicator of your metabolic health
• Why a simple skin incision is often the only cure for a stubborn abscess
• General anaesthesia is a controlled state of unconsciousness, but how it works remains mysterious.
• End-of-life care is about honoring personal values as much as managing physical symptoms.
• Is the permanent reshaping of your cornea worth the risk of chronic dry eyes?
• Can legal CBD products trigger a positive result on a workplace drug test?

More in Medical procedures · More in Health · Latest · A–Z · All topics